Credit Suisse’s Evolent Health EVH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $47.4M | Sell |
1,444,064
-223,038
| -13% | -$7.12M | 0.05% | 389 |
|
|
2023
Q4 | $55.1M | Sell |
1,667,102
-91,869
| -5% | -$2.6M | 0.05% | 358 |
|
|
2023
Q3 | $47.9M | Sell |
1,758,971
-49,586
| -3% | -$1.38M | 0.05% | 388 |
|
|
2023
Q2 | $54.8M | Buy |
1,808,557
+6,959
| +0.4% | +$225K | 0.05% | 377 |
|
|
2023
Q1 | $58.5M | Sell |
1,801,598
-548,369
| -23% | -$17.3M | 0.06% | 348 |
|
|
2022
Q4 | $66M | Sell |
2,349,967
-118,563
| -5% | -$3.4M | 0.07% | 297 |
|
|
2022
Q3 | $88.7M | Sell |
2,468,530
-282,210
| -10% | -$9.94M | 0.1% | 214 |
|
|
2022
Q2 | $84.5M | Sell |
2,750,740
-121,278
| -4% | -$3.53M | 0.09% | 233 |
|
|
2022
Q1 | $92.8M | Sell |
2,872,018
-29,204
| -1% | -$765K | 0.08% | 275 |
|
|
2021
Q4 | $80.3M | Sell |
2,901,222
-906,409
| -24% | -$26M | 0.04% | 450 |
|
|
2021
Q3 | $118M | Sell |
3,807,631
-186,264
| -5% | -$4.47M | 0.07% | 308 |
|
|
2021
Q2 | $83.6M | Sell |
3,993,895
-169,149
| -4% | -$3.39M | 0.04% | 451 |
|
|
2021
Q1 | $84.1M | Buy |
4,163,044
+60,698
| +1% | +$1.15M | 0.04% | 471 |
|
|
2020
Q4 | $65.8M | Buy |
4,102,346
+347,923
| +9% | +$4.6M | 0.03% | 583 |
|
|
2020
Q3 | $46.6M | Buy |
3,754,423
+2,341
| +0.1% | +$27.5K | 0.03% | 637 |
|
|
2020
Q2 | $26.7M | Buy |
3,752,082
+8,844
| +0.2% | +$59.2K | 0.02% | 807 |
|
|
2020
Q1 | $20.3M | Sell |
3,743,238
-2,643
| -0.1% | -$23.6K | 0.02% | 835 |
|
|
2019
Q4 | $33.9M | Buy |
3,745,881
+128,588
| +4% | +$1.04M | 0.02% | 740 |
|
|
2019
Q3 | $26M | Buy |
3,617,293
+363,414
| +11% | +$2.61M | 0.02% | 763 |
|
|
2019
Q2 | $25.9M | Buy |
3,253,879
+1,413,887
| +77% | +$16.7M | 0.02% | 782 |
|
|
2019
Q1 | $23.1M | Buy |
1,839,992
+1,795,834
| +4,067% | +$28.4M | 0.02% | 788 |
|
|
2018
Q4 | $881K | Buy |
44,158
+15,798
| +56% | +$365K | ﹤0.01% | 2884 |
|
|
2018
Q3 | $805K | Sell |
28,360
-42,872
| -60% | -$1.02M | ﹤0.01% | 3017 |
|
|
2018
Q2 | $1.5M | Buy |
71,232
+2,939
| +4% | +$55.6K | ﹤0.01% | 2703 |
|
|
2018
Q1 | $973K | Buy |
68,293
+7,312
| +12% | +$105K | ﹤0.01% | 2971 |
|
|
2017
Q4 | $750K | Buy |
60,981
+171
| +0.3% | +$2.41K | ﹤0.01% | 3196 |
|
|
2017
Q3 | $1.08M | Buy |
60,810
+39,393
| +184% | +$812K | ﹤0.01% | 3039 |
|
|
2017
Q2 | $543K | Buy |
21,417
+2,273
| +12% | +$54.7K | ﹤0.01% | 3102 |
|
|
2017
Q1 | $427K | Sell |
19,144
-71,645
| -79% | -$1.38M | ﹤0.01% | 3379 |
|
|
2016
Q4 | $1.34M | Buy |
90,789
+52,369
| +136% | +$1.03M | ﹤0.01% | 2785 |
|
|
2016
Q3 | $945K | Buy |
38,420
+19,204
| +100% | +$449K | ﹤0.01% | 3009 |
|
|
2016
Q2 | $369K | Buy |
+19,216
| New | +$264K | ﹤0.01% | 3588 |
|
|
2016
Q1 | – | Sell |
-14,039
| Closed | -$170K | – | 4047 |
|
|
2015
Q4 | $170K | Sell |
14,039
-24,848
| -64% | -$366K | ﹤0.01% | 3952 |
|
|
2015
Q3 | $621K | Buy |
+38,887
| New | +$759K | ﹤0.01% | 3236 |
|
Other funds holding EVH
RCM
RSCM
EC
Credit Suisse's EVH Position: Q1 2024 in Review
Credit Suisse reduced its Evolent Health (EVH) stake by 13% in Q1 2024, selling an estimated $7.12M and leaving 1,444,064 shares worth $47.4M. The position accounts for 0.05% of the portfolio, ranked #389.
Credit Suisse first reported a position in EVH in Q3 2015 and has held it in 34 quarters since. The position peaked at $118M in Q3 2021. 251 funds tracked by Wall St. Rank hold EVH as of Q1 2024.
- Credit Suisse held 1,444,064 shares of Evolent Health worth $47.4M as of Q1 2024.
- Credit Suisse sold 223,038 Evolent Health shares in Q1 2024, an estimated $7.12M.
- Evolent Health made up 0.05% of Credit Suisse's portfolio in Q1 2024, its #389 holding.
- Credit Suisse first reported a position in Evolent Health in Q3 2015 and has held it in 34 quarters since.
- Credit Suisse's Evolent Health position peaked at $118M in Q3 2021.
- 251 funds tracked by Wall St. Rank held Evolent Health as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.